Dr. Simon has been awarded a grant focused on understanding the underlying biological mechanisms that cause many patients treated with CAR T-cell therapy to experience the dangerous, toxic immune response called cytokine release syndrome (CRS). The researchers will test pharmaceutical agents for CRS prevention and treatment.
Content courtesy of Leukemia & Lymphoma Society
PUBLISHED RESEARCH
Simon S, Bugos G, Prins R, Rajan A, Palani A, Heyer K, Stevens A, Zeng L, Thompson KA, Atilla PA, Price JP, Kluesner MG, Jaeger-Ruckstuhl CA, Shabaneh TB, Olson JM, Su X, Riddell SR. Design of sensitive monospecific and bispecific synthetic chimeric T cell receptors for cancer therapy. Nat Cancer. 2025.
Simon S, Bugos G, Salter AI, Riddell SR. Synthetic receptors for logic gated T cell recognition and function. Curr Opin Immunol. 2022.